v3.26.1
Segment reporting (Details 2)
₨ in Millions, $ in Millions
 12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
INR (₨)
Mar. 31, 2024
INR (₨)
Disclosure of operating segments [line items]        
Revenues ₨ 335,933 [1] $ 3,580 ₨ 325,535 [1] ₨ 279,164 [1]
Global Generic [Member]        
Disclosure of operating segments [line items]        
Revenues 299,033   289,552 245,453
Global Generic [Member] | Oncology [member]        
Disclosure of operating segments [line items]        
Revenues 63,131   85,798 67,563
Global Generic [Member] | Nervous System [Member]        
Disclosure of operating segments [line items]        
Revenues 61,292   43,345 29,760
Global Generic [Member] | Pain Management [Member]        
Disclosure of operating segments [line items]        
Revenues 30,114   27,552 23,990
Global Generic [Member] | Gastrointestinal [Member]        
Disclosure of operating segments [line items]        
Revenues 27,620   25,315 23,368
Global Generic [Member] | Respiratory [Member]        
Disclosure of operating segments [line items]        
Revenues 21,868   17,034 16,326
Global Generic [Member] | Cardiovascular [Member]        
Disclosure of operating segments [line items]        
Revenues 21,204   18,551 17,291
Global Generic [Member] | Anti-Infective [Member]        
Disclosure of operating segments [line items]        
Revenues 13,196   12,774 15,896
Global Generic [Member] | Diabetology [Member]        
Disclosure of operating segments [line items]        
Revenues 12,432   7,452 5,336
Global Generic [Member] | Hematology [Member]        
Disclosure of operating segments [line items]        
Revenues 8,346   8,628 10,949
Global Generic [Member] | Dermatology [Member]        
Disclosure of operating segments [line items]        
Revenues 8,132   6,427 5,680
Global Generic [Member] | Nutraceutical [Member]        
Disclosure of operating segments [line items]        
Revenues 8,020   9,130 7,691
Global Generic [Member] | Others [Member]        
Disclosure of operating segments [line items]        
Revenues ₨ 23,678   ₨ 27,546 ₨ 21,603
[1] Revenues for the year ended March 31, 2026 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, of Rs.7,270 (as compared to Rs.9,389 and Rs.10,707 for the years ended March 31, 2025 and 2024, respectively) and from the PSAI segment to the Others segment of Rs.0 (as compared to Rs.0 and Rs.72 for the years ended March 31, 2025 and 2024, respectively)